CLINICAL_TRIALS ClinicalTrials.gov record update

Brachytherapy With Durvalumab (MEDI4736) and Tremelimumab in Subjects With Platinum-Resistant or Refractory and Recurrent or Metastatic Gynecological Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04395079
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:28.944852+00:00
Published At: 2026-02-09T00:00:00+00:00
Record Updated At: 2026-02-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Malignant Female Reproductive System Neoplasm", "Platinum-Resistant Malignant Female Reproductive System Neoplasm", "Recurrent Malignant Female Reproductive System Neoplasm", "Refractory Malignant Female Reproductive System Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-09"
protocolSection.identificationModule.nctId: "NCT04395079"
protocolSection.identificationModule.officialTitle: "Brachytherapy With Durvalumab (MEDI4736) and Tremelimumab in Subjects With Platinum-Resistant or Refractory and Recurrent or Metastatic Gynecological Malignancies"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.